Sign inJoin waitlistJoin the waitlist

Christopher Fletcher

Associate Professor · University of Wisconsin Hospitals and Clinics

Credentials: · · · ·

History

University of Wisconsin Hospitals and Clinics
Present

Hematology and Medical Oncology
University of Wisconsin Hospitals and Clinics
2016–2019
Fellowship in Hematology and Medical Oncology
2013–2016
William S Middleton Memorial Veterans Hospital
2010–2013
Internal Medicine
University of Wisconsin Hospitals and Clinics
2007–2010
Loyola University Chicago Stritch School of Medicine
2003–2007

Research

Activation induces shift in nutrient utilization that differentially impacts cell functions in human neutrophils
Proceedings of the National Academy of Sciences of the United States of America · 2024 · 19 citations
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403
Blood Cancer Journal · 2025 · 3 citations
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
Clinical Lymphoma · 2026 · 1 citations

Anna Huttenlocher
2 papers
BK
Brad Kahl
2 papers
Craig Portell
2 papers
Jonathon Cohen
2 papers
Jorgo Lika
2 papers
JC
Julie Chang
2 papers
Saurabh Rajguru
2 papers
Stefan Schieke
2 papers
Vaishalee Kenkre
2 papers
Adam Burr
1 paper
Andrew Evens
1 paper
BM
Brett Morris
1 paper · 1 as a resident

Clinical trials

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
Principal investigator · Recruiting
University of Wisconsin, Madison
2022–2026
Split-Dose R-CHOP for Older Adults With DLBCL
Principal investigator · Active not recruiting · Phase 2
University of Wisconsin, Madison
2021–2027
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2038
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027